FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/04/051858 [Registered on: 21/04/2023] Trial Registered Prospectively
Last Modified On: 20/04/2023
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Ayurveda 
Study Design  Randomized, Parallel Group, Placebo Controlled Trial 
Public Title of Study   Efficacy of Triphaladi Ghana Vati, Udvartana and lifestyle modification in the management of Sthaulya (overweight) in children 
Scientific Title of Study   Efficacy of Triphaladi Ghana Vati, Udvartana and lifestyle modification in the management of Sthaulya (overweight) in children - An open labelled randomized placebo controlled clinical trial 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Anita Yadav 
Designation  MD Scholar 
Affiliation  Institute of Teaching and Research in Ayurveda Jamnagar 
Address  Department of Kaumarbhritya 5th floor ITRA Jamnagar Gujarat 361008 India

Jamnagar
GUJARAT
361008
India 
Phone  7073914239  
Fax    
Email  yadavanitaa6@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Sagar M Bhinde 
Designation  Assistant Professor 
Affiliation  Institute of Teaching and Research in Ayurveda Jamnagar 
Address  Department of Kaumarbhritya 5th floor ITRA Jamnagar Gujarat 361008 India

Jamnagar
GUJARAT
361008
India 
Phone  9662512158  
Fax    
Email  sgrbhinde@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Dr Sagar M Bhinde 
Designation  Assistant Professor 
Affiliation  Institute of Teaching and Research in Ayurveda Jamnagar 
Address  Department of Kaumarbhritya 5th floor ITRA Jamnagar Gujarat 361008 India

Jamnagar
GUJARAT
361008
India 
Phone  9662512158  
Fax    
Email  sgrbhinde@gmail.com  
 
Source of Monetary or Material Support  
Dept. of Kaumarbhritya, 5th floor, Institute Building, ITRA, Jamnagar 
 
Primary Sponsor  
Name  Institute of Teaching and Research in Ayurveda Jamnagar 
Address  Opposite Reliance smart ITRA Jamnagar 
Type of Sponsor  Research institution and hospital 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Anita Yadav  PG Hospital Institute of Teaching and Research in Ayurveda   OPD no 15, OPD Building, Institute of Teaching and Research in Ayurveda
Jamnagar
GUJARAT 
7073914239

yadavanitaa6@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institutional Ethics Committee Institute of Teaching and Research in Ayurveda Jamnagar  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:E663||Overweight. Ayurveda Condition: ATISTHAULYAM (KEVALA-KAPHA),  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmProcedure-udvartanam, उद्वर्तनम् (Procedure Reference: Astanga Hridya Sutra Sathana 2/14, Procedure details: Udvartana with Yava Kulattha (dry powder) Churna will be done in the Pratiloma direction for 20min. daily in the morning or evening empty stomach for the Initial 15 days.)
2Intervention ArmLifestyle--Dinacarya: Patients will be asked to schedule their wake-up time between 6 am to 7 am (irrespective of their school timing). Brushing the teeth, evacuation of Mala, bath should do every morning. 25 to 30 minut, Ritucarya: , Acara Rasayana:, Other:, Pathya/Apathya:yes, Pathya:Cereals: Kodrava, Yava (Barley), Rice flakes, Oats, Ragi, Suji (Semolina), Puffed rice, Bajara (Millets), Jowar (Sorghum).Pulses: Moongdal (Green gram), Rajma (Kidney beans), Chanak (Chick peas), Masoordal (Lentils), Kulattha (Horse gram), Matar (Pea), Arhara (Pigeon peas). Vegetables: Raja Kshvaka (Pumpkin), Patola (Pointed gourd), Lauki (Ridge gourd), Karela (Bitter gourd), Paalak (Spinach), Broccoli, Brinjal, Mulaka (Radish), Grunjanaka (Carrot),Cabbage, Cucumber, Mushroom, Cauliflo, Apathya:Godhuma, Naveen dhanya. Masha, Tila Potato, Street foods, Fast foods, Chips, Namkeens, Biscuits, Samosa, Kachori Chocolates, Toffies, Mithai and all excess sugar containing items. Pizza, Burger, French fries, Sandwich, etc Cold Drinks, Soda, Packaged and Canned Milk Shakes & Juices. Curd, Paneer, Tea & Coffee, Bakery Products
3Intervention ArmLifestyle--Dinacarya: , Ritucarya: , Acara Rasayana:, Other:Exercise -[for 25 to 30 min.]: Start with a Prayer and Prandharna (2min.), Surya Namaskara (5Rounds, 2min.), Tadasana (45sec.), Utkatasana (45sec.), Vakrasana/ Ardha Matsyaendrasana (1min.), Janu Sirasana/ Paschimottanasana (1min.), Ustrasana (1min.), Pavan Muktasana (45sec.), Setu Bhandasana (1min.), Makrasana (2min.), Bhujangasana (1min.), Shavasana (1min.), Kapalbhati (25strokes, 2min.), Nadi Shodhan/ Anulam-Vilom (3 rounds, 1min.), Surya Bhedana Pranayama (3rounds, 1min.), Bhramari Pran, Pathya/Apathya:, Pathya:, Apathya:
4Comparator ArmDrugOther than Classical(1) Medicine Name: Placebo Vati, Reference: NA, Route: Oral, Dosage Form: Gutika/Vati/Ghana Vati/Tablets, Dose: 500(mg), Frequency: tds, Bhaishajya Kal: Pragbhakta, Duration: 8 Weeks, anupAna/sahapAna: Yes(details: -Lukewarm Water), Additional Information: -
5Intervention ArmDrugClassical(1) Medicine Name: Triphaladi Ghana vati, Reference: Charak sutra sthana 23/10-11, Route: Oral, Dosage Form: Gutika/Vati/Ghana Vati/ Tablets, Dose: 500(mg), Frequency: tds, Bhaishajya Kal: Pragbhakta, Duration: 8 Weeks, anupAna/sahapAna: Yes(details: -Lukewarm Water), Additional Information: -
 
Inclusion Criteria  
Age From  10.00 Year(s)
Age To  16.00 Year(s)
Gender  Both 
Details  1. Children aged between 10-16 years, irrespective
of gender.
2. Individuals having BMI between 85th to 95th
percentile of CDC growth charts.
3. Individuals with any 4 classical signs and
symptoms of Sthaulya i.e., Chala Sphika Udara
Stana, Aalasya/Utsah hani, Kshudra shwasa/
Aayasen shwasa, Nidraadhikya, Swedaadhikya,
Daurgandhya, Atipipasa, Atikshudha. 
 
ExclusionCriteria 
Details  Children who are known cases of any systemic, endocrinal illness like Diabetes Mellitus
(Type-1), Thyroid disorders, Hypertension, Coronary Heart Disease (CHD), Asthma etc.
or known cases of any psychiatric or genetic disorders.
• Children who are known case of drug induced obesity and taking such drugs at present as well 
 
Method of Generating Random Sequence   Other 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Primary Outcome: Change in the BMI and S. Adiponectin. (BT and AT)
✓ Secondary Outcome: Changes in anthropometric measurements (every 7 days), S. lipid
and in classical signs and symptoms of Sthaulya. (BT and AT)
 
Primary Outcome: Change in the BMI and S. Adiponectin. (BT and AT)
✓ Secondary Outcome: Changes in anthropometric measurements (every 7 days), S. lipid
and in classical signs and symptoms of Sthaulya. (BT and AT)
 
 
Secondary Outcome  
Outcome  TimePoints 
Changes in anthropometric measurements (every 7 days), S. lipid
and in classical signs and symptoms of Sthaulya. (BT and AT)
 
8 wks 
 
Target Sample Size   Total Sample Size="40"
Sample Size from India="40" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   05/05/2023 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)   Not Yet Recruiting 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   yet not published 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary   Introduction: Childhood overweight is growing in leaps and bounds, and becoming an epidemic health problem across the globe. It is pioneer to many lifestyle disorder. Thus, apart from malnutrition, overweight is a new rising concern in India. It is the new emerging epidemic that needs to be taken cared well in time. Significance: In the contemporary science there are only few treatment modalities for overweight like weight loss drugs (Hyroxycut, Meratrim and Orlistat), bariatric surgery (liposuction) and lifestyle interventions (diet and exercise). However, others except lifestyle intervention have known side effects. Because of limitations and inconsistency in tackling this problem, and the complications associated with contemporary health care system, this research topic has been selected. Ayurveda has mentioned detailed management of overweight under the heading of Sthaulya and Santarpanotha Vyadhi. Ayurveda treatment comprises Shamana as well as Shodhana therapy along with lifestyle modification. Various researches have also shown promising results with the help of these Ayurveda treatments in overweight children. Aim and Objectives: To evaluate the efficacy of Triphaladi Ghana Vati, Udvartana and lifestyle modification, in the management of Sthaulya (overweight) in children. Materials and Methods: 40 Children of either sex aged between 10-16 years with any 4 classical signs and symptoms of Sthaulya i.e., Chala Sphika Udara Stana, Aalasya/Utsah hani, Kshudra shwasa/ Aayasen shwasa, Nidraadhikya, Swedaadhikya, Daurgandhya, Atipipasa, Atikshudha will be enrolled in two groups. Group A: Trial group: Triphaladi Ghana Vati internal; Udvartana with Yava Kulattha, and life style modification. Group B: Placebo control group: Placebo drug and life style modification  Results and Discussion: Data generated during the above study will be presented in a systemic manner and shall be analyzed statistically. Follow up: After completion of therapy, follow up will be done for 4 weeks (visit in every 15 days) to assess the status of patient, where the patient will be asked to report. Adverse effects: This proposal will be reviewed and approved by ITRA, Institutional Ethics Committee, which is having the responsibility to protect the research participants from harm. These drugs have no known unwanted effects. It is possible that it may also cause some problems that we are not aware of. Adverse drug reactions if any observed will be reported to the Pharmacovigilance cell of ITRA. 
Close